Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF)and may include paid advertising.

• CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, just announced that a total of 3,320,000 warrants were exercised for the purchase of 3,320,000 common shares at $0.10 a share.
• Debentures aggregating $190,000 of principal were also converted into 1,520,000 shares at a conversion price of $0.125 a share.
• 1,520,000 shares were exercised by the settlement of $152,000 of debt, with cash proceeds of $180,000 from the exercise of warrants for 1,800,000 shares applied to working capital.
• CMX’s President and CEO, Jan Alston, noted that this milestone demonstrates the confidence of the company’s management, directors, and supporting shareholders.

CMX (CSE: CXC) (OTC: CXXMF), an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, just announced that a total of 3,320,000 warrants were exercised for the purchase of 3,320,000 common shares of the company at $0.10 a share. In addition, debentures aggregating $190,000 of principal were converted into 1,520,000 shares at a conversion price of $0.125 a share (https://ibn.fm/C4Sni).

“The exercise of warrants and conversion of debentures demonstrates the confidence of management, directors, and supporting shareholders in CMX’s plan to advance the Clayton Silver project,” noted Jan Alston, President and CEO of CMX. “This kind of support over the past decade has positioned the company to capitalize on the current precious metals bull market, which in our opinion is still in its early stages,” he added (https://ibn.fm/C4Sni).

The exercised warrants were issued under a private placement completed back in 2021. Of the total issued warrants, 1,520,000 shares were exercised by the settlement of $152,000 of debt, with cash proceeds of $180,000 from the exercise of warrants for 1,800,000 shares applied to working capital.

This marks a key moment for CMX, specifically for its 100%-owned flagship asset, the Clayton Silver property located in the Bayhorse Mining District of central Idaho. It is also timely, given that, beginning in the spring of this year, the company plans to conduct the first comprehensive geophysical program over the mine and its surrounding structures, including a 3-D Direct Current Induced Polarization (“DCIP”) survey and a Magnetotelluric (“MT”) survey. The surveys will delineate known structures, identify extensions of partially mined historic ore bodies, and look for parallel vein systems, as well as potential deeper sources of mineralization. These are important steps preceding diamond drilling planned to test priority targets (https://ibn.fm/AaLhL).

Mining operations at the company’s Clayton Silver property date back to the early 1900’s when Henry Ford owned the claims for the lead production. From 1935 to 1986, operations were continuous, with recorded production over those 50 years totaling approximately 7 million ounces of silver, along with lead, zinc, copper, and minor gold from an estimated 2.15 million tons of ore (https://ibn.fm/BUtb3). Over the next several years, CMX’s management expects to put a sizable investment into its drilling programs to realize the site’s significant untapped potential.

For company information, visit the company’s website at www.CMXGoldandSilver.com.

NOTE TO INVESTORS: The latest news and updates relating to CXXMF are available in the company’s newsroom at https://ibn.fm/CXXMF

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF)and may include paid advertising.

• The company has signed an option agreement to acquire a 100% interest in the Hopkins Rare Earths Project in northern Ontario.
• The property covers approximately 5,900 hectares within the Clay-Howells Alkalic Rock Complex, and a geological setting associated with rare earth element (“REE”) exploration, with planned exploration includes airborne geophysics, radiometric surveys, mapping, and geochemical sampling.
• Management says the acquisition strengthens Powermax’s growing North American REE portfolio alongside projects in British Columbia, Ontario, and Wyoming.
• Growing Western interest in domestic REE supply chains continues to support exploration activity across Canada and the United States.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America, is continuing to expand its rare earth element exploration portfolio with the proposed acquisition of the Hopkins Rare Earths Project in northern Ontario, a move that further cements the company’s role within the growing North American critical minerals sector.

The company announced that it has entered into an option agreement to acquire a 100% interest in the Hopkins project, subject to a 2% net smelter returns royalty (https://ibn.fm/1e2yn). The Hopkins property consists of 13 multicell mining claims covering approximately 5,900 hectares in Hopkins and Mowbray townships in northern Ontario. The area is accessible through existing regional infrastructure, including the Trans-Canada Highway, provincial roads, logging routes, and nearby transportation corridors.

Management said the project aligns with the company’s broader strategy of assembling a diversified portfolio of REE-focused exploration opportunities across stable North American jurisdictions.

The geological interest surrounding the property centers on its location within the Clay-Howells Alkalic Rock Complex, a Late Precambrian intrusive system situated within the Kapuskasing Subprovince of the Superior Province. Historical geological work in the broader area has identified alkalic intrusive rocks, carbonatites, magnetite-rich zones, breccias, and alteration features that are often associated with REE-bearing systems.

According to Powermax, the Hopkins property exhibits geological characteristics considered favorable for carbonatite-related REE exploration. Historical work referenced by the company also identified nearby occurrences of monazite and cerium-lanthanum-calcium silicate mineral phases, although the company cautioned that nearby mineralization does not necessarily indicate similar mineralization on the Hopkins property itself.

The acquisition expands Powermax’s existing portfolio, which already includes the Cameron REE property in British Columbia, the Atikokan and Pinard projects in Ontario, and the Ogden Bear Lodge project in Wyoming.

Chief Executive Officer Paul Gorman said the Hopkins acquisition provides the company with a sizeable land package in a geological setting known for alkalic intrusive and carbonatite-related rocks commonly associated with rare earth exploration systems. “We believe the Property has strong early-stage exploration merit and fits well with our strategy of acquiring projects with favourable geology, infrastructure access and scalable exploration potential,” he said.

The company plans to begin a Phase 1 exploration program focused on refining exploration targets and identifying prospective zones across the property. Proposed work includes desktop geological and geophysical compilation, GIS modeling, field prospecting, mapping, rock and soil sampling, and airborne magnetic and gamma-ray spectrometric surveys. Radiometric surveying will also play a role in the early-stage program. Handheld scintillometers are expected to be used to identify radiometric anomalies that may correlate with REE-bearing mineralization. Subject to Phase 1 results, management indicated future work could include trenching, more detailed geophysics, and diamond drilling programs.

The expansion comes amid growing geopolitical focus on securing domestic supplies of rare earth elements and other critical minerals. REEs are essential components in permanent magnets, electric vehicles, wind turbines, military systems, advanced electronics, and numerous industrial technologies.

Global supply chains remain heavily concentrated in China, which currently dominates both REE mining and downstream processing capacity. According to industry estimates cited by the company, China controls roughly 60% of global rare earth mining and approximately 90% of processing activity. That concentration has intensified efforts by Western governments to support alternative supply chains. In both Canada and the United States, policymakers have increasingly classified rare earth elements as strategically important minerals tied to energy transition goals and national security priorities.

The United States has used measures including the Defense Production Act to direct funding toward domestic and allied critical mineral projects. Canadian companies may also qualify for certain North American funding initiatives tied to strategic mineral development.

Powermax remains at the exploration stage, and the Hopkins project itself is still in the early evaluation phase. The company emphasized that historical geological and mineralogical information has not yet been fully verified under current reporting standards and that further exploration will be required to determine the extent of any mineralized zones.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)and may include a paid advertisement.

• SureNano has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide targeting metabolic disease.
• Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies.
• The company’s vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats.
• SureNano is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials.
• The company provides exposure to the expanding GLP-1 and obesity treatment markets, which are projected to grow significantly over the coming years.

SureNano (CSE: SURE) (OTCQB: SURNF) is a Canadian life sciences company positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. Blockbuster drugs such as Ozempic(R), Wegovy(R), and Mounjaro(R) have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments.

Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic. Through its acquisition of GlucaPharm Inc., the company holds an exclusive license to develop GEP-44, a novel peptide discovered at Syracuse University, and is progressing the asset through the U.S. Food and Drug Administration (“FDA”) pathway with the goal of advancing it into clinical development.

The company’s strategy centers on combining therapeutic innovation with its foundational expertise in formulation and drug delivery to improve tolerability, administration, and patient experience. By focusing on a targeted development pathway within a rapidly expanding market dominated by large incumbents, SureNano aims to position its lead asset as a potential candidate for future partnership or acquisition as it progresses through clinical milestones.

The company is headquartered in Vancouver, British Columbia.

Portfolio

SureNano’s operations are now centered on the development of its lead therapeutic candidate, GEP-44, through its wholly owned subsidiary, GlucaPharm Inc. This asset represents the company’s primary focus as it advances its transition into a pharmaceutical development platform targeting metabolic disease.

GEP-44 is a novel, patented, monomeric peptide developed at Syracuse University that functions as a triple agonist targeting GLP-1 and peptide YY (“PYY”) receptors Y1 and Y2, which has demonstrated significant weight reduction and blood glucose normalization in preclinical studies, without the nausea and gastrointestinal side effects commonly associated with first-generation GLP-1 drugs currently on the market. This mechanism is designed to integrate glucose regulation, appetite suppression, and improved tolerability within a single molecule, addressing limitations commonly associated with first-generation GLP-1 therapies. GEP-44 is exclusively licensed from Syracuse University and represents a second-generation GLP opportunity targeting comparable or superior efficacy with improved patient tolerability.

In preclinical studies, GEP-44 demonstrated approximately 15% weight loss compared to 9% for liraglutide, along with a 39% reduction in food intake versus 20% for the comparator, while also improving glucose control and showing no observed gastrointestinal side effects such as nausea and vomiting.

The asset is being advanced through IND-enabling studies in collaboration with a contract research organization, with planned progression into clinical trials. SureNano’s foundational expertise in nanotechnology and formulation science, including its SureNano(TM) emulsifier platform, supports the development of potential non-injectable delivery formats such as oral, nasal, or sublingual administration.

The IND-enabling Good Laboratory Practice toxicology and pharmacology study program for GEP-44 is vital to de-risk the company’s lead candidate and is designed to support its strategy of launching a Phase I clinical trial in Australia, which is expected to be in collaboration with a premier global contract research organization (“CRO”), LabCorp, known for its expertise in preclinical development (subject to entering into definitive collaboration agreements). The pivotal, GLP-compliant package is specifically designed to assess safety, toxicology, and pharmacology across multiple species, including rodents and non-rodent primates, to evaluate the safety and feasibility of the approach for human clinical application. The studies will provide comprehensive data to determine the maximum tolerated dose (“MTD”), identify potential biomarkers for monitoring toxicity, assess the reversibility of toxic effects, and establish the safety margin needed for first-in-human studies.

Market Opportunity

SureNano is targeting the global market for metabolic disease therapeutics, which continues to expand due to rising rates of obesity and Type II diabetes. Company materials indicate that the GLP-1 therapeutic market was valued at approximately $24 billion in 2026 and is projected to reach approximately $33 billion by 2030.

The broader obesity treatment market, which includes all therapeutic approaches, was valued at approximately $15.9 billion in 2024 and is forecast to exceed $60 billion by 2030. These trends are supported by global prevalence estimates suggesting that approximately one billion people could be obese by 2030, reinforcing sustained demand for effective pharmacological interventions.

Within this landscape, GLP-based therapies are experiencing strong growth, with long-term projections indicating a multi-hundred-billion-dollar market opportunity over the coming decade. SureNano’s strategy is to position GEP-44 as a next-generation alternative within this category, with a focus on improved tolerability and delivery to expand patient adoption. SureNano’s platform is focused on advancing a differentiated GLP-1 asset with the potential for non-injectable administration, including oral, sublingual, or nasal delivery, which management believes could materially expand patient adoption and long-term market penetration.

As GEP-44 advances through IND, Phase I, and Phase II-III development towards FDA approval, management expects SureNano to be positioned as one of the only micro-cap public companies developing GLP-1 technology, with direct exposure to the multi-hundred-billion-dollar GLP-1 metabolic market, and the potential to compete alongside large pharmaceutical incumbents, based on current preclinical results.

Leadership Team

Charles MaLette, Chief Executive Officer, President and Director, has more than 35 years of experience as an investment advisor with Canaccord Genuity Corp., where he focused on financing, analyzing, and advising public companies across multiple industries, and holds a degree in economics from the University of Calgary along with a teaching degree from the University of British Columbia.

James Bordian, Chief Financial Officer and Director, is a retired Chartered Accountant and Certified Internal Auditor with over 40 years of experience, including senior management roles at organizations such as Air Canada and BC Hydro, with expertise in financial reporting, tax planning, and business valuation.

Dr. Nihar Pandey, Chief Scientific Officer, is a biochemist and clinical researcher with more than 25 years of experience in drug discovery and development, having developed multiple IP-protected formulations, published extensively in peer-reviewed journals, and held roles at institutions including the University of Ottawa Heart Institute, Liponex Inc., and Health Canada.

Dr. Robert Doyle, Inventor and Advisor, is a medicinal chemist focused on drug development for obesity and type 2 diabetes, with specialization in peptide and protein design, recombinant expression, bioconjugate chemistry, and drug delivery. He joined Syracuse University in 2005, was named the Laura J. and L. Douglas Meredith Professor in 2016 and Dean’s Professor of Chemistry in 2022, and also holds an appointment as Associate Professor of Medicine at SUNY.

Dr. Peter Billing, Obesity Expert and Advisor, is a Mayo-trained metabolic bariatric surgeon, entrepreneur, and clinical investigator who serves as a courtesy medical staff member at Swedish First Hill and holds leadership roles including Medical Director at Transform SurgiCenter. He has a robust publication record on surgical treatments and bariatric procedures and was named a Top Doctor by Castle Connolly in 2023.

For more information, visit the company’s website at www.SureNano.com.

NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF

Forward-Looking Information

Forward-looking information involves numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking information. These risks and uncertainties include, among other items: market prices, study and trial results, continued availability of capital and financing, and general economic, market, or business conditions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what the Company currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include: expectations regarding the size of the markets the company operates in; the ability of the Company to successfully achieve its business objectives; plans for growth, political, social and environmental uncertainties; presence of laws and regulations which may impose restrictions in the markets where the Company operates; market volatility; fluctuations in investor sentiment; changes in the Company’s business plans; and trial and study results. Accordingly, readers should not place undue reliance on forward-looking information and statements. Readers are cautioned that reliance on such information and statements may not be appropriate for other purposes.  The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. The Company does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.

Prospective Investors Should Consult with their Advisors.

The information contained in this presentation does not purport to be all-inclusive or to contain all information that a prospective investor may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Corporation and of the information contained in this presentation. Without limitation, prospective investors should consider the advice of their financial, legal, accounting, tax and other advisors and such other factors they consider appropriate in investigating and analyzing the Corporation. All amounts are expressed in Canadian dollars unless otherwise noted. The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release or promotional content.

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement.

• SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants.
• The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy.
• The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes.
• The company is also exploring acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments.
• SureNano’s transition toward a pharmaceutical-focused model follows its acquisition of GlucaPharm, now operating in the rapidly expanding GLP market expected to hit $200 billion in sales by 2030.

SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, has begun a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The company is initiating a Good Laboratory Practice (“GLP”) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (“FDA”) requirements, intended to support an Investigational New Drug (“IND”) application and represents a necessary step before first-in-human clinical trials. Against a backdrop of a rapidly expanding GLP market, SureNano is positioning itself as an agile entrant in the next-generation GLP-1 landscape having developed a patented high-performing second-generation incretin-based therapy after securing licensing rights to the GEP-44 compound developed by Syracuse University.

The GLP economic opportunity is substantial with the global GLP-1 receptor agonist market projections range from $100 billion to J.P. Morgan estimates of the broader incretin market to reach $200 billion by 2030, with ~25 million by 2030 patients using GLP-1 therapies in the United States alone. SureNano is participating in one of the fastest-growing and most commercially significant therapeutic markets in modern healthcare, with the GEP-44 contender that performs with higher tolerability and a friendly administration method, including greater weight loss, enhanced glucose control and an absence of the gastrointestinal side effects than first-generation therapies.

The studies are expected to be conducted in collaboration with Labcorp, a contract research organization (“CRO”) specializing in preclinical development services to support clinical development, subject to final agreements and funding (https://ibn.fm/xo3MQ).

According to the company, the GLP-compliant program will evaluate safety, toxicology, and pharmacology across multiple species, including rodents, non-rodents, and primates. The objective is to determine the maximum tolerated dose, identify biomarkers for monitoring toxicity, assess whether adverse effects are reversible, and establish safety margins for initial human testing. 

Following completion of the studies, SureNano plans to submit a Clinical Trial Notification in Australia, where it intends to begin Phase I trials. The company cited Australia’s regulatory framework and clinical research infrastructure as factors supporting an accelerated pathway to first-in-human studies.

Dr. Nihar Pandey, Chief Scientific Officer at SureNano, said the program marks a transition toward clinical-stage evaluation. “Initiating these U.S. Food and Drug Administration IND-enabling studies is a major milestone for SureNano Science and GlucaPharm, moving us firmly towards the final, rigorous evaluation in various clinical phases before entering the clinic,” said Dr. Pandey. “Partnering with a globally renowned CRO like LabCorp will ensure our studies meet the highest regulatory standards. This package is vital to de-risk our lead candidate and is designed to support our strategy of launching a Phase I clinical trial in Australia.”

GEP-44, the company’s lead asset, is being developed through subsidiary GlucaPharm, which SureNano acquired earlier in 2026. The peptide was originally developed at Syracuse University and is designed as a multi-receptor agonist targeting pathways involved in glucose regulation and appetite control, designed as a triple agonist targeting GLP-1 and peptide YY (“PYY”) receptors (“Y1” and “Y2”), combining glucose regulation, appetite suppression, and improved tolerability within a single molecule.

It is positioned within the same therapeutic category as widely prescribed GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro. Those drugs have reshaped treatment approaches for obesity and type 2 diabetes and contributed to rapid growth in the GLP-1 market, which industry estimates place at tens of billions of dollars annually, with continued expansion expected.

SureNano said its candidate is designed to address some of the limitations associated with current therapies, including gastrointestinal side effects and the need for injectable delivery. The company is also exploring alternative delivery methods, including oral, sublingual, and nasal formats, which could affect patient adherence if successfully developed.

At this stage, GEP-44 remains in preclinical development, and its efficacy and safety in humans have not yet been established. The IND-enabling program is intended to generate the data required for regulators to evaluate whether human trials can proceed.

In parallel with its metabolic disease program, SureNano said it has begun discussions to acquire or license intellectual property related to Ibogaine formulations. Ibogaine is a naturally occurring psychoactive compound that has been studied for potential use in treating addiction and certain mental health conditions.

The company said it is in early-stage discussions with academic institutions and research groups regarding synthesis, formulation, and delivery technologies for Ibogaine and related compounds. No agreements have been finalized, and management noted that there is no assurance that any transaction will be completed.

Interest in Ibogaine has increased in recent years alongside broader research into psychedelic-assisted therapies. Recent regulatory developments in the United States, including IND clearance for Ibogaine-related studies, have opened the possibility of controlled clinical trials, although the field remains at an early stage.

SureNano’s approach reflects a broader shift in its business model. The company began with a focus on nanotechnology and formulation science, including the development of its SureNano(TM) emulsifier, a plant-derived compound used to improve stability and bioavailability in various applications.

Following the acquisition of GlucaPharm, the company has moved toward a pharmaceutical development strategy centered on therapeutic candidates with potential applications in large and growing healthcare markets. Obesity and type 2 diabetes remain among the most significant global health challenges, with prevalence rates rising and healthcare systems facing increasing costs associated with long-term management.

For more information, visit the company’s website at www.SureNano.com.

NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF

Forward-Looking Information

Forward-looking information involves numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking information. These risks and uncertainties include, among other items: market prices, study and trial results, continued availability of capital and financing, and general economic, market, or business conditions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what the Company currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include: expectations regarding the size of the markets the company operates in; the ability of the Company to successfully achieve its business objectives; plans for growth, political, social and environmental uncertainties; presence of laws and regulations which may impose restrictions in the markets where the Company operates; market volatility; fluctuations in investor sentiment; changes in the Company’s business plans; and trial and study results. Accordingly, readers should not place undue reliance on forward-looking information and statements. Readers are cautioned that reliance on such information and statements may not be appropriate for other purposes.  The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. The Company does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.

Prospective Investors Should Consult with their Advisors.

The information contained in this presentation does not purport to be all-inclusive or to contain all information that a prospective investor may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Corporation and of the information contained in this presentation. Without limitation, prospective investors should consider the advice of their financial, legal, accounting, tax and other advisors and such other factors they consider appropriate in investigating and analyzing the Corporation. All amounts are expressed in Canadian dollars unless otherwise noted. The Canadian Securities Exchange (CSE) has not reviewed and does no

• The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation
• The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents
• Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration

In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control. With biotech capital markets remaining selective and the IPO window constrained, alternative models that preserve shareholder value while advancing pipelines are gaining traction.

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself within that shift. In an April 24 corporate update, the company outlined a partnership-driven strategy designed to unlock the value of its intellectual property portfolio while maintaining a capital-efficient operating structure.

A Capital-Efficient Framework

The foundation of Oncotelic’s approach is its joint venture with GMP Biotechnology. Through this structure, the company retains a 45% interest in GMP Bio while enabling the advancement of a complementary pipeline of oncology and rare disease candidates. The financial impact was notable: an independent third-party valuation contributed a $249 million increase to Oncotelic’s balance sheet for the most recent fiscal year.

For a clinical-stage company, that outcome represents more than a one-time accounting event. It provides a validated framework for advancing assets without issuing additional equity or taking on traditional financing obligations. Management has indicated that this model is being actively pursued across additional partnerships, with discussions ongoing.

“Our joint venture strategy has demonstrated the ability to unlock value through strategic partnerships,” said CEO Dr. Vuong Trieu, reinforcing the company’s intent to scale this approach across its broader portfolio.

Depth of Intellectual Property

The ability to execute a partnership-driven model depends heavily on the underlying assets. Oncotelic’s portfolio is anchored by an extensive intellectual property base, including more than 500 patent applications and 75 issued patents developed under the leadership of Dr. Trieu.

Rather than relying on a single lead candidate, the company can structure multiple co-development agreements, licensing deals, or joint ventures across distinct therapeutic targets. Its focus areas, including oncology, TGF-beta therapeutics, and rare pediatric indications, align with sectors where larger pharmaceutical companies often seek external innovation.

In this context, each patent represents a potential entry point for partnership, enabling the company to pursue parallel development pathways without concentrating risk in a single program.

The AI Acceleration Layer

In addition to its therapeutic pipeline, Oncotelic is advancing its proprietary PDAOAI platform, which integrates artificial intelligence into research, biomarker discovery, and regulatory workflows. The company recently announced the integration of approximately 28 million scientific abstracts into the platform, representing a broad aggregation of available scientific knowledge.

This dataset is being embedded into a robotics platform developed in collaboration with TechForce Robotics, with initial commercial deployments expected in the near term. The combined system is designed to automate elements of pharmaceutical development and manufacturing, improving efficiency while reducing reliance on manual processes.

Strategically, the AI layer extends beyond operational efficiency. By accelerating target identification and development timelines, it enhances the attractiveness of Oncotelic’s assets to potential partners, strengthening the economics of future collaborations.

Scaling the Partnership Model

Management has indicated that additional partnerships are under active negotiation, suggesting that the GMP Bio structure may represent the first in a series of similar arrangements. The combination of a validated joint venture framework, a deep intellectual property portfolio, and an operational AI platform provides flexibility in structuring deals tailored to specific assets and indications.

For investors evaluating microcap biotechnology companies, this model represents a departure from the traditional binary outcome associated with single-asset development. Instead of relying on a single clinical readout, Oncotelic is pursuing a portfolio-based strategy where value can be realized through multiple partnership-driven events.

In a sector where capital constraints often dictate outcomes as much as science, the ability to advance multiple programs while limiting dilution may prove to be a meaningful differentiator. Oncotelic’s approach suggests that, in today’s biotech environment, how a company structures its partnerships can be as important as the assets it develops.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

• Rising power demands from satellites, AI workloads, and space-based infrastructure are creating a new bottleneck in orbit
• Planet Ventures recent investment in Mantis Space highlights Planet’s strategy of backing foundational technologies in high-growth sectors
• The company recently announced the appointment of Dr. Bora to its leadership team, bringing experience in science, technology, and innovation

Planet Ventures (CSE: PXI) (OTC: PNXPF) is strategically positioning itself at the forefront of a critical shift in the global space economy: the race to build scalable energy infrastructure in orbit. As satellite networks expand and new applications such as space-based data centers and AI processing emerge, power—not launch capacity—is increasingly becoming the defining constraint on future growth.

For decades, the industry has focused on getting assets into space. Today, attention is shifting toward how those assets are powered. Mega-constellations, persistent satellite operations, and next-generation applications all require reliable, continuous energy, something current systems are not yet designed to deliver at scale. At the same time, rising energy demand on Earth, driven in part by artificial intelligence, is placing increasing strain on terrestrial grids, accelerating innovation beyond the planet.

Planet Ventures’ recent USD$200,000 investment in Mantis Space reflects this shift (ibn.fm/PAYyS). Mantis Space is developing what it describes as the world’s first orbital energy grid designed to deliver power directly to satellites, space habitats, and future lunar systems. This concept introduces a new category within the space economy: energy distribution as a service in orbit.

Momentum behind this thesis continues to build. As satellite volumes grow and mission complexity increases, energy is emerging as a key bottleneck. The rise of space-based data centers, designed to support energy-intensive AI workloads, further amplifies the need for scalable, always-on power solutions. While orbital environments offer advantages such as near-constant solar exposure, the absence of distribution infrastructure limits the ability to fully harness that energy.

Mantis Space is strategically positioning itself to solve this challenge. Its orbital grid is created to enable persistent satellite operations, defense applications, on-orbit manufacturing and future lunar infrastructure, capabilities generally seen as vital to a space economy expected to exceed $1 trillion in the coming years.

Planet Ventures, an investment issuer focused on aerospace and space innovation, seeks to provide shareholders with exposure to high-growth opportunities that are often limited to private markets. By targeting early-stage companies building foundational infrastructure, the firm is aligning its portfolio with long-term structural trends shaping the next phase of economic expansion.

Further reinforcing this strategic direction, Planet Ventures recently announced the appointment of Dr. Bora to its leadership team, bringing deep expertise in science, technology, and innovation. This addition underscores the company’s commitment to strengthening its technical and strategic capabilities as it scales its investment platform within the rapidly evolving space sector.

These developments highlight Planet Ventures’ broader mission: to invest in transformative technologies that enable the next wave of global growth. As the space economy matures, energy infrastructure is emerging not only as a critical opportunity, but also as a defining constraint.

For more information, visit www.PlanetVenturesinc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000 to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. 

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding: Planet Ventures’ investment strategy and objectives; anticipated developments in the commercial space industry, including the growth of orbital energy and space robotics markets; the projected growth of the global space economy; Planet Ventures’ expectations regarding the strategic importance of its investments in Mantis Space and General Astronautics; the anticipated role of orbital energy technologies and robotic servicing systems in future in-orbit operations; and the potential for these technologies to become foundational to the next generation of commercial space activity.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

• Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
• Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
• Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
• Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
• Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
• Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
• Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
• Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities

• Global energy markets are looking beyond traditional oil basins as reserve depletion and supply pressures intensify.
• Greenland Energy Company is focused on Greenland’s Jameson Land Basin, a high-potential and largely underexplored hydrocarbon region.
• The company aims to unlock frontier-scale energy resources that support long-term supply security and strategic diversification.

Greenland Energy (NASDAQ: GLND) is positioning itself within a shifting global energy landscape, as policymakers and industry leaders increasingly look beyond traditional oil-producing regions in search of new, scalable hydrocarbon resources. Years of underinvestment in upstream development, combined with reserve depletion in mature basins and rising geopolitical instability, are driving renewed interest in frontier exploration.

Ongoing tensions across key producing regions, and persistent disruptions at strategic chokepoints such as the Strait of Hormuz, continue to underscore the fragility of global energy supply chains. Despite ongoing diversification efforts, long-term energy security remains a central concern for Western economies, prompting increased focus on underexplored regions capable of supporting future production (ibn.fm/XgJFZ).

Within this context, Greenland is emerging as one of the last largely untapped hydrocarbon basins globally. Its expansive Arctic geology presents significant resource potential at a time when conventional discoveries are becoming harder to achieve. Rather than relying on aging fields, operators are increasingly evaluating frontier basins that offer district-scale opportunity and long-term development upside.

Greenland Energy Company’s primary focus is the Jameson Land Basin in eastern Greenland – a vast, historically underexplored region spanning more than two million acres across three onshore licenses that cover the entire petroleum basin. Unlike more mature oil provinces, where much of the accessible value has already been realized, Jameson Land represents a longer-duration exploration opportunity with meaningful upside potential (ibn.fm/9Z2YW).

Importantly, the basin is not without precedent. Between the 1970s and 1990s, Atlantic Richfield (“ARCO”) invested more than $275 million (inflation-adjusted) into seismic acquisition, field mapping, and geological evaluation across the region, identifying multiple large hydrocarbon targets. However, these efforts stopped short of drilling, leaving the basin effectively untested (ibn.fm/FZrd3).

Building on this historical foundation, Greenland Energy has reprocessed approximately 1,800 kilometers of legacy seismic data using modern imaging technologies, identifying more than 50 oil and gas leads and prospects. The basin has been compared geologically to prolific producing regions such as the North Sea and Alaska’s Prudhoe Bay, reinforcing its potential significance within the global energy landscape.

The company has structured its position through agreements that could allow it to earn up to a 70% interest in the basin, contingent on the drilling of initial exploration wells. Operational planning is actively advancing, with major industry service providers already engaged, including Halliburton for logistics and drilling support, IPT Well Solutions for project management, and Stampede Drilling for rig operations. These steps signal a transition from historical analysis toward tangible field execution.

From a resource perspective, the broader Arctic is estimated to contain approximately 13% of the world’s undiscovered conventional oil and 30% of its undiscovered natural gas. Within that framework, independent engineering analysis has suggested the Jameson Land Basin could hold significant recoverable oil potential, highlighting the scale of the opportunity—while still subject to the inherent uncertainties of exploration. As global demand for reliable energy sources continues to grow, Greenland Energy Company’s positioning reflects a broader shift toward securing long-term resource optionality. Its presence in Greenland places it at the intersection of exploration and strategic supply development, offering exposure to a region that could play a more prominent role in the global energy mix over time.

Taken together, these developments underscore the company’s core objective: to unlock large-scale hydrocarbon potential in one of the world’s least developed energy regions. By concentrating on the Jameson Land Basin, Greenland Energy Company is aligning its strategy with the increasing importance of resource security, long-term supply visibility, and basin-scale opportunity in a rapidly evolving energy environment.

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at ibn.fm/GLND

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

• Canadian near-term gold producer LaFleur Minerals is increasing its holdings within the prolific Abitibi Greenstone Belt in Quebec through the value-accretive acquisition of the 78.5-square-kilometer McKenzie East Gold Project
• LaFleur has already been conducting an exploratory drilling operation at its nearby Swanson Gold Project, which has been shown to have broad, continuous zones of gold mineralization
• Swanson, and now McKenzie East, have the potential to serve as sources of feedstock for LaFleur’s Beacon Gold Mill, which the company expects to restart later this quarter by building from 750 metric tons per day (TPD) of output to 1,250 TPD by the end of its first year
• LaFleur’s acquisition agreement provides for 100% interest in McKenzie East Gold Project, a property contiguous to Fresnillo plc’s McKenzie Break Project

Near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is announcing a strategic, value-accretive acquisition that adds to the company’s expectations of building revenue this year through its vertically integrated mine-to-mill gold production strategy. 

LaFleur is the owner of the 19,214 hectare Swanson Gold Project in the prolific Val-d’Or mining district and has now expanded its gold portfolio by acquiring a new, nearby gold project, McKenzie East. The new acquisition adds just over 1,781 hectares with 46 mineral claims in the McKenzie East Gold Project, part of the Val-d’Or region and contiguous with Fresnillo’s McKenzie Break Gold Deposit, which holds a historic high-grade indicated resource of 146,000 ounces of gold at 3.2 grams per tonne and an inferred resource of 250,600 ounces at 3.1 grams per tonne (https://ibn.fm/T2knP).

The McKenzie Break Gold Deposit is owned by Fresnillo plc, the world’s leading primary silver producer and a major global gold miner, according to LaFleur’s announcement. A 2021 drill program completed by the previous owner of McKenzie East Gold Project found anomalous gold mineralization, and LaFleur plans to explore the potential to define gold resources, which intends to complement the company’s mine-to-mill production model leveraging its 100%-owned Beacon Gold Mill in the same region.

LaFleur plans to use a 100,000 mt bulk sample from its Swanson Gold Project to restart gold production at its nearby Beacon Gold Mill, along with an existing 10,000 to 20,000 metric tons of feedstock at the Beacon site for test runs, with first gold pour anticipated for next quarter. The mill was idled a couple of years ago by its previous owner, but remains in a state of near-readiness, and the McKenzie acquisition creates an additional potential source of mill feed to build revenues over the long-term.  

LaFleur anticipates beginning its milling operation by processing mineralized material at a rate of 750 metric tons per day (“TPD”). The company expects to build to 1,000 TPD and then to 1,250 TPD during the first year of resumed mill operation, with support from recently announced financing terms received from Trafigura Canada to fund this scale-up, then to begin moving toward a target of 3,000 to 4,000 TPD in a sustainable operation. 

Recent record price levels for the gold market have created excitement throughout the industry. LaFleur CEO and Director Paul Ténière has said the company’s cautious but aggressive strategy is built on an all-in sustaining costs (“AISC”) standard of US$1,569 per ounce of gold and calculated on a base case of $2,750 per ounce of gold, leaving a large margin of opportunity between it and the market’s level in early May of approximately $4,700 per ounce (https://ibn.fm/lBr3S).

Exploration at the Swanson Gold Project has led LaFleur to expect a large-scale and expanding gold system with broad, continuous zones of gold mineralization and significant expansion potential at depth. 

The company’s three-tiered revenue model draws on the opportunity to employ its mineable land holdings within the Abitibi Gold Belt, Swanson and now McKenzie, sourced of mineralized material to feed production at its Beacon Gold Mill, completed by a tailings pond on site.

LaFleur’s agreement with the Vendor will grant it a 100% interest in the McKenzie East Gold Project following a cash payment of $30,000 as well as the issuance of 175,000 common shares of LaFleur Minerals Inc. to the Vendor, subject to exchange approval.

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

• American Fusion(TM) launched a Government Procurement Services segment alongside its fusion energy development business.
• The company announced an initial transaction tied to a Canadian Department of National Defence procurement requirement.
• The approximately $58,000 purchase order involves specialized RF measurement equipment supplied through Canadian contractor Effective Acceleration Ventures Ltd.
• Management views the procurement segment as a way to build institutional and defense-sector relationships while its fusion platform continues development.
• Through subsidiary Kepler Fusion Technologies, the company continues to develop the Texatron(TM) fusion platform for modular energy applications.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, is expanding beyond its core energy initiatives with the launch of a Government Procurement Services operating segment. The move reflects an effort to diversify operational activities while building relationships within defense and institutional procurement channels.

The company recently announced an initial transaction supporting a Canadian defense requirement. According to the announcement, American Fusion(TM) received a purchase order from Effective Acceleration Ventures Ltd. (“EAV”) to supply two 53100A Phase Noise Analyzer units for use under a Canadian Department of National Defence (“DND”) and Quality Engineering Test Establishment (“QETE”) contract (https://ibn.fm/It6wu).

The purchase order carries an estimated value of approximately $58,000, excluding shipping and related pass-through expenses. American Fusion(TM) is acting as a United States source-of-supply vendor for instrumentation manufactured by Microchip Technology, while EAV serves as the Canadian prime contractor to DND/QETE.

Management described the transaction as modest financially but strategically relevant because it demonstrates the company’s ability to participate in specialized procurement and supply-chain processes linked to government and defense organizations.

The equipment involved, the 53100A Phase Noise Analyzer, is used in precision timing and RF measurement applications, including oscillator characterization, frequency stability analysis, and signal integrity testing. Such systems are commonly used across aerospace, communications, electronics, and defense environments where signal precision is critical.

American Fusion(TM) said the new Government Procurement Services segment will operate independently from its fusion development activities conducted through subsidiary Kepler Fusion Technologies. The company stated that the segment is intended to focus on technical sourcing, institutional procurement support, and participation in government-related supply opportunities.

Samuel Reid, who serves as Government Strategy and Procurement Advisor to American Fusion(TM) and separately as a director of EAV, helped coordinate the transaction. Management indicated that the procurement initiative could eventually support relationships involving defense, Department of Energy, and NATO-related programs.

The expansion comes as American Fusion(TM) continues developing its broader energy strategy through Kepler Fusion Technologies and the Texatron(TM) fusion platform. The company previously changed its corporate identity following the merger with Kepler, repositioning itself around advanced energy infrastructure and fusion-related technologies.

Fusion energy remains an emerging field attracting both government and private capital globally. Developers are attempting multiple approaches to achieve commercially viable fusion systems capable of generating large-scale power with limited emissions and reduced long-term fuel constraints compared with conventional energy generation.

American Fusion(TM) is pursuing a modular approach through the Texatron(TM) platform. According to company statements, Kepler is currently developing multiple reactor configurations intended for industrial, commercial, and grid-related deployment scenarios.

Management has discussed plans involving both a smaller 5-megawatt demonstration system and a larger 100-megawatt commercial-scale design. The modular structure is intended to allow additional generation capacity to be added incrementally over time.

Although the technology is still in development, investor interest in fusion-related businesses has increased over the past several years as governments and private-sector participants search for long-duration energy solutions capable of supporting electrification, artificial intelligence infrastructure, manufacturing growth, and grid modernization.

American Fusion(TM) appears to be positioning itself at the intersection of those long-term energy ambitions and near-term institutional contracting opportunities. The newly announced procurement segment may offer a practical operating track capable of generating commercial activity while the company continues the longer development cycle associated with fusion technologies.

Chief Executive Officer Richard Hawkins described the Canadian defense-related transaction as an early validation of the procurement strategy and the company’s ability to operate within institutional purchasing environments. “This is an important milestone because it demonstrates our ability to participate in real-world procurement environments through an ancillary operating track distinct from our fusion development activities,” said Brent Nelson, Founder and Executive Director of American Fusion. “We believe engagements of this type can support broader institutional relationships over time.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, sees 2026 as an exciting year for its Montauban Gold-Silver Project in Quebec
• While appearing on The MiningNewsWire Podcast, Gordon Robb, ESGold’s CEO, noted that the company has now laid down the needed foundations, and has a number of important milestones coming up
• The foundations include securing all equipment and making significant progress on its 20,000 sq. ft. processing facility, which followed a C$7.2 million raise from the sale of 10,683,000 units of the company at C$0.68 a unit

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, recognizes what an exciting period it is for the company, not just from a growth perspective, but also from a resource extraction standpoint for its flagship Montauban Gold-Silver Project in Quebec. While appearing on the latest episode of The MiningNewsWire Podcast , Gordon Robb, ESGold’s CEO reiterated the company’s progress thus far this year, while pointing out the company’s ambitions and why 2026 is a significant year for the company.

“2026 is a very big year for us. We have secured all our equipment…We’re currently building out our facility at a very fast pace. We’re aiming to be in operations this year, coupled with our maiden drill campaign kicking off,” he noted (https://ibn.fm/2r3N4).

Over the past few months, ESGold has been on an ambitious endeavor to raise money geared toward the exploration and development of its Montauban property. It recently raised gross proceeds of C$7.2 million from the sale of 10,683,000 units of the company at C$0.68 a unit, ultimately setting the stage for initiatives that have never been seen on the property over its entire history (https://ibn.fm/vZePh).

In March, the company shared results from its initial ANT survey and integrated 3D model, which revealed a deep and expanding mineralized corridor extending to approximately 900 meters and over at least two kilometers of strike. The company further announced an expanded program to confirm whether the interpreted structural corridor continues along strike, with the goal of identifying the property’s full extent and potential.

“This is a past-producing mine that produced for well over 100 years, yet with very limited property-wide exploration…That leaves us with an exciting opportunity, because this is a known mine that has never had modern exploration techniques applied across the entire property,” Robb noted. “We have a lot of milestones coming up, and at the same time we’re developing, exploring and aiming to be producing all in the same year,” he added (https://ibn.fm/2r3N4).

It is an ambitious plan for ESGold, but things are now in place to mark 2026 as the company’s most defining year thus far. Robb has expressed his confidence in his team, noting what a great period it is for them as they move toward achieving the said milestones. 

“I can confidently say for myself and my team, there’s not a lot of sleep going on, but this is an exciting period for us as we move quickly toward these major milestones,” he noted (https://ibn.fm/2r3N4).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF